Moleculin Biotech, Inc. (MBRX) financial statements (2020 and earlier)

Company profile

Business Address 5300 MEMORIAL DRIVE
HOUSTON, TX 77007
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11785
Cash and cash equivalents11785
Receivables0   
Prepaid expense3110
Other undisclosed current assets(0)   
Total current assets:13885
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0000
Intangible assets, net (including goodwill), including:11111111
Other undisclosed intangible assets, net (including goodwill)11111111
Total noncurrent assets:12121111
TOTAL ASSETS:25201916
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4421
Accounts payable211 
Accrued liabilities121 
Interest and dividends payable   0
Other undisclosed accounts payable and accrued liabilities   1
Debt   0
Deferred compensation liability 0  
Derivative instruments and hedges, liabilities 01 
Total current liabilities:4421
Noncurrent Liabilities
Long-term debt and lease obligation0   
Operating lease, liability0
Liabilities, other than long-term debt6100
Deferred compensation liability, classified  00
Deferred rent credit 0
Derivative instruments and hedges, liabilities61  
Total noncurrent liabilities:6100
Total liabilities:10521
Stockholders' equity
Stockholders' equity attributable to parent, including:16141715
Common stock0000
Additional paid in capital55413220
Accumulated deficit(40)(26)(14)(5)
Other undisclosed stockholders' equity attributable to parent00  
Total stockholders' equity:16141715
TOTAL LIABILITIES AND EQUITY:25201916

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:  0 
Operating expenses(18)(15)(9)(4)
Other undisclosed operating loss  (0) 
Operating loss:(18)(15)(9)(4)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
0(0)  
Interest and debt expense   (0)
Loss from continuing operations before income taxes:(18)(15)(9)(4)
Income tax benefit0   
Net loss:(17)(15)(9)(4)
Other undisclosed net income (loss) attributable to parent43(1) 
Net loss available to common stockholders, diluted:(13)(12)(10)(4)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(17)(15)(9)(4)
Comprehensive loss:(17)(15)(9)(4)
Other undisclosed comprehensive income, net of tax, attributable to parent43  
Comprehensive loss, net of tax, attributable to parent:(13)(12)(9)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: